GLP1R and obesity due to melanocortin 4 receptor deficiency: GLP-1 receptor agonists now represent a cornerstone of therapy for both T2DM and obesity, with consistent benefits on glycemic control, body weight, and cardiovascular and renal outcomes [129, 255].